Business context and reporting period
The supplied filing is a Form 10-Q for AFH Acquisition X, Inc., a development-stage blank-check company, for the three months ended January 31, 2012. It reports no active operations other than searching for a business combination; no target negotiations were underway. Filing identity discrepancy: the request metadata names Bone Biologics Corp., but the filing text identifies AFH Acquisition X, Inc. Investors should verify the registrant and filing before relying on this summary.
Financial highlights
| Metric | Three months ended Jan. 31, 2012 | Comparable period / balance |
|---|---|---|
| Revenue | $0 | $0 in 2011 |
| Net loss | $1,356 | $1,275 in 2011 |
| Expenses | $1,356, all legal and professional | $1,275 in 2011 |
| Cash and total assets | $0 at Jan. 31, 2012 | $0 at Oct. 31, 2011 |
| Total liabilities | $30,324 | $28,968 at Oct. 31, 2011 |
| Accumulated deficit | $55,324 | $53,968 at Oct. 31, 2011 |
| Cash flows | $0 operating cash flow and $0 ending cash | $0 ending cash in 2011 |
Liabilities comprised $6,276 of accrued expenses and $24,048 due to the parent, AFH Holding & Advisory, LLC. The parent advance has no stated repayment terms. The company reported no revenue, and margins are not meaningful. It disclosed no separate debt balance, guidance, or forecast.
Changes, outlook, and risks
- Quarterly net loss increased by $81 from the prior-year quarter; accrued expenses rose by $1,356 from October 31, 2011.
- Management said the company depends on raising capital or acquiring a marketable company to continue. It had no capital resources at quarter-end and expected to rely on stock issuance and shareholder contributions for administrative expenses.
- The filing warns that a business combination is uncertain, additional equity funding may not be available, and an acquisition could significantly dilute existing shareholders. The company reported recurring operating losses and an accumulated deficit of $55,324; its going-concern presentation depends on future financing or an acquisition.
- No legal proceedings or material off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective and reported no significant changes in internal controls during the quarter.
Important facts to verify
- Confirm whether this AFH Acquisition X filing is the intended filing for Bone Biologics Corp.
- Verify the reported zero cash and assets against the company’s financing needs and the $30,324 of liabilities.
- Review the parent advance’s repayment expectations and any future funding commitments; the filing provides no repayment terms.
- Assess the company’s ability to fund operations and complete a business combination, including potential dilution and going-concern risk.